In 2021, the platform achieved an Authorization to Operate with Conditions (ATO-C) from the Department of the Air Force for conducting IL4 meetings.

We discussed biological therapeutic options, including anti IgE, anti IL5 and anti IL4 receptor alpha, including different mechanisms of action, side effect profiles, frequency of injections and ...